It’s no secret, your body goes through some major changes during pregnancy. A lesser known fact is some expecting women experience vision changes pre-and post-partum.
How come my vision changed after I had a baby?
Approximately 20 percent of women experience this, according to Arian Fartash, OD. “The reason is because a lot of hormone changes go on when you’re pregnant.”
Hormones play a significant role in fluid retention so when estrogen levels are elevated, women tend to retain more water than usual. Just as many women will experience swollen feet, your eyes can swell too which could cause vision changes. The fluid retention can change the shape of the cornea which changes the way light passes through the eye, distorting one’s vision.
“It starts at the beginning of pregnancy, when your hormones are going all over the place,” said Dr. Fartash.
Your vision may return to normal once the hormones level out, but you could also experience the change permanently.
Dr. Fartash explains what you should do if you notice vision changes when you’re expecting in this episode of #AskAnEyeDoc:
Whether you’re pregnant or not, you should consult with your eye doctor if you notice any changes in your vision. Don’t have an eye doctor? Use our Find a Doctor tool for a quick and easy way to locate your nearest VSP network provider.
Need a vision care plan? Check out all the available individual plans to meet your eye care needs.
If you have a general eye-related question, be sure to comment below or post to social media with hashtag #AskAnEyeDoc.
Disclaimer: Information received through VSP Vision Care’s social media channels is for informational purposes only and does not constitute medical advice, medical recommendations, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial. The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
ProQR, a biotech company in the Netherlands, ha s reported vision improvements for patients in a Phase 1/2 clinical trial for QR-110 , a therapy for people with Leber congenital amaurosis 10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world. The company reported that 60 percent of su bjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course . The treatment was also safe for patients. As a result of the encouraging interim results, ProQR has concluded the Phase 1/2 trial and plans to move the treatment into a Phase 2/3 clinical trial. Ten people were treated in the Phase 1/2 study. Results from the interim analy sis were presented on September 5, 2018, at the Retinal Degeneration 2018 meeting in Killarney, Ireland , by principal investigator Artur Cideciyan , PhD , research professor of ophthalmology at the Scheie Eye Ins...
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
Comments
Post a Comment